Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial - Quiz - MDSpire

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

  • By

  • Solange Peters

  • Daniel S. W. Tan

  • David E. Gerber

  • James Urbanic

  • Suresh Ramalingam

  • Jinming Yu

  • Ligang Xing

  • Achim Rittmeyer

  • Tudor-Eliade Ciuleanu

  • Juliana de Menezes

  • Hye Ryun Kim

  • Carlos Rojas

  • Konstantinos Syrigos

  • Hidetoshi Hayashi

  • Anoop Haridass

  • Diego Cortinovis

  • Debora Bruno

  • Martin Kimmich

  • Antonio Calles

  • Raheel Nathani

  • Geetha Pudussery

  • Luoying Yang

  • Dirk De Ruysscher

  • May 13, 2026

  • 0 min

Share

Original Source(s)

Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial

  • by Solange Peters, Daniel S. W. Tan, David E. Gerber, James Urbanic, Suresh Ramalingam, Jinming Yu, Ligang Xing, Achim Rittmeyer, Tudor-Eliade Ciuleanu, Juliana de Menezes, Hye Ryun Kim, Carlos Rojas, Konstantinos Syrigos, Hidetoshi Hayashi, Anoop Haridass, Diego Cortinovis, Debora Bruno, Martin Kimmich, Antonio Calles, Raheel Nathani, Geetha Pudussery, Luoying Yang, Dirk De Ruysscher

  • May 13, 2026

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

Real-world treatment patterns and outcomes for patients with extensive-stage small-cell lung cancer treated in US community oncology practices

Editorial: Epigenetic modulation in cancer